logo-loader

Oragenics Inc

Receive alerts
Market:
NYSE
Market Cap:
$21.33 m
Price
0.46 USD
Change
-2.92%
52 weeks high
1.04
52 weeks low
0.36

In brief

We are focused on becoming a leader in novel antibiotics against infectious disease and on developing effective treatments for oral mucositis. Oragenics, Inc. has established two exclusive worldwide channel collaborations with Intrexon Corporation and its subsidiaries. The collaborations allow Oragenics to accelerate the development of much needed new antibiotics that can work against resistant strains of bacteria and the development of biotherapeutics for oral mucositis and other diseases and conditions of the oral cavity, throat, and esophagus.